SCHEMBL23976333

SCHEMBL23976333

O=C1CCc2cc(C(F)(F)F)ncc21

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 2/20 0.40
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
HTR1A P08908 1/20 0.36
DRD2 P14416 1/20 0.36
HTR2A P28223 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP11B1 P15538 1/20 0.36
CYP11B2 P19099 1/20 0.36
MAOA P21397 1/20 0.36
CHEK1 O14757 1/20 0.35
FLT3 P36888 1/20 0.35
PBRM1 Q86U86 1/20 0.34
HSD17B1 P14061 2/20 0.34
MKNK1 Q9BUB5 1/20 0.33
TRPV4 Q9HBA0 1/20 0.33
PARP10 Q53GL7 2/20 0.33
PARP15 Q460N3 1/20 0.33
PARP14 Q460N5 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30062124 1.00 MAOB (0.40) MAOBCASP1CASP7HSD17B10HTR1A
SCHEMBL23376852 0.76 CASP1 (0.41) MAOBCASP1CASP7HSD17B10CYP1A2
SCHEMBL30488170 0.72 MAOA (0.43) MAOBMAOACHEK1FLT3
SCHEMBL14107455 0.72 MAOA (0.43) MAOBMAOACHEK1FLT3
SCHEMBL23376854 0.72 CASP1 (0.41) MAOBCASP1CASP7HSD17B10HTR1A
SCHEMBL1915610 0.72 CYP1A2 (0.42) CASP1CASP7HSD17B10CYP1A2CYP11B1
SCHEMBL16798334 0.72 CASP1 (0.41) MAOBCASP1CASP7HSD17B10CYP1A2
SCHEMBL23376933 0.72 CASP1 (0.41) MAOBCASP1CASP7HSD17B10CYP1A2
SCHEMBL30415198 0.72 CASP1 (0.41) MAOBCASP1CASP7HSD17B10CYP1A2
SCHEMBL31696565 0.71 IDO1 (0.48) MAOBCYP1A2CYP11B1CYP11B2PBRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220401422-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE NOVARTIS AG (CH) 2022-12-22 US disclosed
WO-2021217508-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-11-04 WO disclosed
WO-2021220170-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE NOVARTIS AG (CH) 2021-11-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220401422-A1 COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE HIF1AN, HIF1A, EGLN2 MAOB 1081/4885CASP1 3853/4885CASP7 3611/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.